Schrödinger, Inc. (SDGR) Stock Price & Analysis

Schrödinger, Inc. (SDGR) closed at USD 22.6 on Thursday, October 22, 2026, down 5.44% on the day. The US market is currently closed (pre-market); this is not a live price.

The prior close was USD 23.9; the Oct 22, 2026 session ranged USD 22.05–24 on volume of 1,628,453 shares. Market capitalization is $1.69B, with a 52-week range of USD 10.95–33.78 (NMS). Source: Nexqual, retrieved October 23, 2026 at 10:03 UTC.

Also available as compact Markdown for AI agents: nexqual.com/SDGR.md

Key facts (SDGR)

• Last four reported quarters (through Jun 30, 2026): revenue $259M, net income -$54.3M (-21.0% margin), free cash flow -$130M (SEC filings).
• 1 of 80 tracked superinvestors hold SDGR (13F, Q2 2026): 0 new, 0 added, 0 reduced, 1 unchanged.
• Insider open-market sales, last ~7 months: 4 Form 4 filings, $2.0M; 0 not under a Rule 10b5-1 plan ($0K); 0 by opportunistic insiders, 0 by routine insiders (three-year test, Cohen, Malloy & Pomorski 2012).
• Analysts: Buy (mean 2.29 on a 1–5 scale) (7 analysts), mean target USD 25.86 (range 17–32).
• Total return with dividends: 1Y +2.9% vs S&P 500 +14.9%; 5Y -57.1% vs S&P 500 +80.3%.
• Next earnings: 2026-11-04, EPS estimate USD -0.67, revenue estimate $47.6M.

Financials (SEC 10-K; TTM = last four 10-Q/10-K quarters) (SDGR)

Fiscal years end Dec. EPS is split-adjusted.

Valuation (price ÷ last four quarters, through Jun 30, 2026) (SDGR)

P/S 6.5x · P/B 5.1x · FCF yield -7.71% · Earnings yield -3.21%

P/E at fiscal year-ends: Dec 2023 65.9x.

Superinvestors (SEC 13F-HR, Q2 2026) (SDGR)

1 of 80 tracked investors hold SDGR. Each row is the investor's latest 13F; change is vs their prior-quarter share count.

Insider sales (SEC Form 4, open-market, last ~7 months) (SDGR)

4 of 4 under a Rule 10b5-1 trading plan (scheduled in advance). Unplanned sales were timed by the insider.

% of holdings sold = shares sold ÷ (shares sold + all holdings the insider reported on that Form 4, direct and through trusts).

Insider type follows Cohen, Malloy & Pomorski (Journal of Finance, 2012). An insider who traded the stock in the same calendar month in each of the past three years is a routine trader; one who traded in each of those years without such a pattern is an opportunistic trader. In their study, trades by opportunistic insiders predicted future returns and trades by routine insiders did not. Counts open-market purchases and sales only (SEC Form 4 codes P and S) by that insider in that company. Not investment advice.

Analysts (SDGR)

Consensus Buy (mean 2.29 on a 1–5 scale), 7 analysts; mean target USD 25.86 (low 17, high 32).

Rating changes, last 120 days:

Total return (dividends reinvested) (SDGR)

SDGR revenue by business segment (quarter ended Jun 30, 2026)

SDGR revenue by product line (quarter ended Jun 30, 2026)

SDGR revenue by region (quarter ended Jun 30, 2026)

As tagged by the company in its SEC 10-Q / 10-K filings (XBRL).

SDGR suppliers, customers and competitors (named in its 10-K)

Quoted from the company's 10-K filed Feb 25, 2026.

SDGR customer concentration

In the period ended Jun 30, 2026, 2 direct customers each accounted for at least 10% (25%, 17%) of revenue, per the company's 10-Q filed Aug 5, 2026. The company does not name them.

SDGR company outlook (results filed Aug 5, 2026)

• “For the third quarter of 2026, ACV is expected to range from $41 million to $45 million, excluding contribution ACV, compared to $38.3 million in the third quarter of 2025, which included $2.2 million of contribution ACV.”

Quoted word-for-word from the SEC 8-K results press release.

SDGR analyst estimates and revisions

SDGR options: expected move

Options price a move of about ±21.0% (±$4.72) by Nov 20, 2026, which includes earnings on Nov 4, 2026. Over the last 8 reports the stock moved ±7% on average.

30-day implied volatility 91.2% vs 107% realized over the last 30 trading days. Put/call ratio (volume) 0.04. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.

Key Statistics (as of October 23, 2026 at 10:03 UTC)

Technical Analysis (SDGR)

Nexqual's technical model rates SDGR "SELL" based on 1 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 10:03 UTC.

Analyst Ratings (SDGR)

Wall Street analysts rate SDGR "Buy" based on 7 analysts, with a mean price target of USD 25.86 (range USD 17–32), per Nexqual as of October 23, 2026 at 10:03 UTC.

Earnings (SDGR)

Recent Earnings History

Source: Nexqual, October 23, 2026 at 10:03 UTC.

Financials & Fundamentals (SDGR)

Source: Nexqual, October 23, 2026 at 10:03 UTC.

Financial Health Score (SDGR)

Nexqual rates Schrödinger, Inc.'s overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 10:03 UTC.

Ownership (SDGR)

Source: Nexqual, October 23, 2026 at 10:03 UTC.

Leadership (SDGR)

Schrödinger, Inc. is led by Ramy Farid, CEO, President & Director, per Nexqual as of October 23, 2026 at 10:03 UTC.

Major Backers & Investors (SDGR)

Notable institutional backers of Schrödinger, Inc. include Gates Foundation Trust, Rubric Capital Management LP, Sumitomo Mitsui Trust Group, Inc., according to Nexqual as of October 23, 2026 at 10:03 UTC.

Active Investors

Index Funds (Passive)

Source: Nexqual, October 23, 2026 at 10:03 UTC.

From Schrödinger, Inc.'s Latest SEC 10-K Filing (filed 2026-02-25)

Key Strengths & Strategy (as disclosed to the SEC)

• In June 2025, the FDA granted fast track designation for SGR-1505 for the treatment of adult patients with Waldenström macroglobulinemia, or WM, that have failed at least two lines of therapy, including a Bruton's tyrosine kinase, or BTK, inhibitor.
• We also leverage our platform and capabilities across a portfolio of collaborative and proprietary drug discovery programs spanning a wide range of disease targets and indications.
• In 2018, we began to develop a pipeline of proprietary drug discovery programs with the goal of using our platform to produce a portfolio of novel, high value therapeutics.
• We intend to maintain our industry-leading position by introducing new capabilities and refining our software to further strengthen our technology and advance the science underlying our platform.

Partnerships

• For example, in November 2024, we entered into an expanded, three-year, software agreement with Novartis, which is more fully described in "—Collaboration Agreements." The three-year agreement substantially increases Novartis' access to our computational predictive modeling technology and enterprise informatics platform to industry-leading scale.
• We are eligible to receive up to $2.272 billion in total milestones across the initial programs, of which no milestone revenue has been recognized as revenue as of December 31, 2025, as well as a tiered percentage royalty on net sales of each product commercialized by Novartis ranging from mid-single-digits to low double-digits, subject to certain specified reductions.

Legal & Regulatory Risks (Item 1A, quoted)

• We have and may continue to seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review designations in the United States, and PRIME Designation in the European Union, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.
• The FDA and comparable regulatory agencies in foreign jurisdictions, play an important role in the development of our product candidates by providing guidance on our programs and reviewing our regulatory submissions. If these oversight and review activities are disrupted, then correspondingly our ability to develop and secure timely approval of our product candidates could be impacted in a negative manner.
• Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and the failure to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition, or results of operations.
• We, and the collaborators who use our computational platform, may be subject to applicable anti-kickback, fraud and abuse, false claims, transparency, health information privacy and security, and other healthcare laws and regulations. Failure to comply with such laws and regulations, may result in substantial penalties.

Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.

Peers & Related Stocks

Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 10:03 UTC. This page is informational and not investment advice.

For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt